Glucagon-like peptide-1 receptor agonists in neoplastic diseases

被引：1
作者：
Ji, Lisan [1 ]
He, Xianzhen [2 ]
Min, Xinwen [1 ]
Yang, Handong [1 ]
Wu, Wenwen [3 ]
Xu, Hao [1 ]
Chen, Jun [1 ,4 ]
Mei, Aihua [1 ]
机构：
[1] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Hubei Clin Res Ctr Hypertens, Hubei Key Lab Wudang Local Chinese Med Res, Shiyan, Peoples R China
[2] Hubei Univ Med, Renmin Hosp, Childrens Med Ctr, Shiyan, Hubei, Peoples R China
[3] Hubei Univ Med, Sch Publ Hlth, Shiyan, Hubei, Peoples R China
[4] Hubei Univ Med, Virol Key Lab Shiyan City, Shiyan, Peoples R China
来源：
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词：
GLP-1RA; tumor diseases; function; mechanism; agonists; PANCREATIC-CANCER CELLS; THYROID C-CELLS; DIABETES-MELLITUS; INSULIN-SECRETION; INHIBITS GROWTH; GLP-1; ANALOG; ACTIVATION; EXENDIN-4; RISK; APOPTOSIS;
D O I：
10.3389/fendo.2024.1465881
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.
引用
收藏
页数：9
相关论文
共 98 条
[21]   Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes [J].
de Graaf, Chris ;
Donnelly, Dan ;
Wootten, Denise ;
Lau, Jesper ;
Sexton, Patrick M. ;
Miller, Laurence J. ;
Ahn, Jung-Mo ;
Liao, Jiayu ;
Fletcher, Madeleine M. ;
Yang, Dehua ;
Brown, Alastair J. H. ;
Zhou, Caihong ;
Deng, Jiejie ;
Wang, Ming-Wei .
PHARMACOLOGICAL REVIEWS, 2016, 68 (04) :954-1013
[22]   Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia [J].
Degn, KB ;
Brock, B ;
Juhl, CB ;
Djurhuus, CB ;
Grubert, J ;
Kim, D ;
Han, J ;
Taylor, K ;
Fineman, M ;
Schmitz, O .
DIABETES, 2004, 53 (09) :2397-2403
[23]   Mechanisms of action of glucagon-like peptide 1 in the pancreas [J].
Doyle, Maire E. ;
Egan, Josephine M. .
PHARMACOLOGY & THERAPEUTICS, 2007, 113 (03) :546-593
[24]   The Cardiovascular Biology of Glucagon-like Peptide-1 [J].
Drucker, Daniel J. .
CELL METABOLISM, 2016, 24 (01) :15-30
[25]   Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies [J].
Elashoff, Michael ;
Matveyenko, Aleksey V. ;
Gier, Belinda ;
Elashoff, Robert ;
Butler, Peter C. .
GASTROENTEROLOGY, 2011, 141 (01) :150-156
[26]   Diabetes mellitus and risk of endometrial cancer: a meta-analysis [J].
Friberg, E. ;
Orsini, N. ;
Mantzoros, C. S. ;
Wolk, A. .
DIABETOLOGIA, 2007, 50 (07) :1365-1374
[27]   Semaglutide lowers body weight in rodents via distributed neural pathways [J].
Gabery, Sanaz ;
Salinas, Casper G. ;
Paulsen, Sarah J. ;
Ahnfelt-Ronne, Jonas ;
Alanentalo, Tomas ;
Baquero, Arian F. ;
Buckley, Stephen T. ;
Farkas, Erzsebet ;
Fekete, Csaba ;
Frederiksen, Klaus S. ;
Helms, Hans Christian C. ;
Jeppesen, Jacob F. ;
John, Linu M. ;
Pyke, Charles ;
Nohr, Jane ;
Lu, Tess T. ;
Polex-Wolf, Joseph ;
Prevot, Vincent ;
Raun, Kirsten ;
Simonsen, Lotte ;
Sun, Gao ;
Szilvasy-Szabo, Anett ;
Willenbrock, Hanni ;
Secher, Anna ;
Knudsen, Lotte Bjerre .
JCI INSIGHT, 2020, 5 (06)
[28]   GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials [J].
Gilbert, Matthew P. ;
Pratley, Richard E. .
FRONTIERS IN ENDOCRINOLOGY, 2020, 11
[29]   Acute Pancreatitis in Association With Type 2 Diabetes and Antidiabetic Drugs A population-based cohort study [J].
Gonzalez-Perez, Antonio ;
Schlienger, Raymond G. ;
Garcia Rodriguez, Luis A. .
DIABETES CARE, 2010, 33 (12) :2580-2585
[30]   Metabolic Messengers: glucagon-like peptide 1 [J].
Gribble, Fiona M. ;
Reimann, Frank .
NATURE METABOLISM, 2021, 3 (02) :142-148
12345678910